AR030911A1 - USE OF N-ARIL-2-SULFONAMIDOBENZAMIDS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CHRONIC RENAL FAILURE AND PHARMACEUTICAL COMPOSITIONS - Google Patents
USE OF N-ARIL-2-SULFONAMIDOBENZAMIDS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CHRONIC RENAL FAILURE AND PHARMACEUTICAL COMPOSITIONSInfo
- Publication number
- AR030911A1 AR030911A1 ARP000103686A ARP000103686A AR030911A1 AR 030911 A1 AR030911 A1 AR 030911A1 AR P000103686 A ARP000103686 A AR P000103686A AR P000103686 A ARP000103686 A AR P000103686A AR 030911 A1 AR030911 A1 AR 030911A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- manufacture
- pharmaceutical compositions
- treatment
- renal failure
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/08—Bridged systems
Abstract
Se describe el uso de N-aril-2-sulfonamidobenzamidas de la formula (1): donde : R1 y R2 se seleccionan independientemente del grupo constituido por hidrogeno, alquilo, alquenilo, arilalquilo, acilo, aroilo, haloalquilo, halo, carboxi, carboalcoxi, carbamoilo, alquilcarbamoilo, arilcarbamoilo, ciano, alcoxi, hidroxilo, fenilazo, amino, nitro, alquilamino, arilamino, arilalquilamino, acilamino, aroilamino, alquiltio, arilalquiltio, ariltio, alquilsulfinilo, arilsulfinilo, arilalquilsulfinilo, alquilsulfonilo, arilsulfonilo, arilalquilsulfonilo, sulfamoilo, arilsulfonamido y alquilsulfonamido; o el resto R1 representa un anillo condensado que forma un benzotiofeno, naftaleno, quinolina, o isoquinolina con el anillo del que es sustituyente; o (R1)n y el anillo del que es sustituyente, representa un heterociclo seleccionado del grupo constituido por tiofeno, furano, piridina, pirimidina, pirazina, y sus benzo-análogos: y R3 se selecciona independientemente del grupo constituido por alquilo, haloalquilo, R1-arilo, y R1-aralquilo, y heterociclos sustituidos con R1 seleccionados del grupo constituido por tiofeno, furano, piridina, pirimidina, pirazina, imidazol, y tiazol, y sus benzo-análogos, que es para la manufactura de un medicamento para inhibir el transporte de fosfato dependiente del sodio, y composiciones farmacéuticas utiles para el tratamiento de la insuficiencia renal cronica y de la enfermedad osea urémica.The use of N-aryl-2-sulfonamidobenzamides of the formula (1) is described: where: R1 and R2 are independently selected from the group consisting of hydrogen, alkyl, alkenyl, arylalkyl, acyl, aroyl, haloalkyl, halo, carboxy, carboalkoxy , carbamoyl, alkylcarbamoyl, arylcarbamoyl, cyano, alkoxy, hydroxyl, phenylazo, amino, nitro, alkylamino, arylamino, arylalkylamino, acylamino, aroylamino, alkylthio, arylalkylthio, arylthio, alkylsulfinyl, arylsulfinyl, arylalkylsulfinyl, alkylsulfonyl, arylsulfonyl, arylalkylsulfonyl, sulfamoyl, arylsulfonamido and alkylsulfonamido; or the R1 moiety represents a condensed ring that forms a benzothiophene, naphthalene, quinoline, or isoquinoline with the ring of which it is substituent; or (R1) n and the ring of which it is a substituent, represents a heterocycle selected from the group consisting of thiophene, furan, pyridine, pyrimidine, pyrazine, and its benzo-analogs: and R3 is independently selected from the group consisting of alkyl, haloalkyl, R1 -aryl, and R1-aralkyl, and R1-substituted heterocycles selected from the group consisting of thiophene, furan, pyridine, pyrimidine, pyrazine, imidazole, and thiazole, and their benzo-analogs, which is for the manufacture of a medicament to inhibit the sodium-dependent phosphate transport, and pharmaceutical compositions useful for the treatment of chronic renal failure and uremic bone disease.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14464699P | 1999-07-20 | 1999-07-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR030911A1 true AR030911A1 (en) | 2003-09-03 |
Family
ID=22509500
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000103686A AR030911A1 (en) | 1999-07-20 | 2000-07-18 | USE OF N-ARIL-2-SULFONAMIDOBENZAMIDS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CHRONIC RENAL FAILURE AND PHARMACEUTICAL COMPOSITIONS |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP1202729A1 (en) |
JP (1) | JP2003504403A (en) |
KR (1) | KR20020015382A (en) |
CN (1) | CN1361687A (en) |
AR (1) | AR030911A1 (en) |
AU (1) | AU6354300A (en) |
BR (1) | BR0012568A (en) |
CA (1) | CA2379657A1 (en) |
CO (1) | CO5190714A1 (en) |
CZ (1) | CZ2002204A3 (en) |
HU (1) | HUP0202938A3 (en) |
IL (1) | IL147697A0 (en) |
MX (1) | MXPA02000753A (en) |
NO (1) | NO20020278L (en) |
NZ (1) | NZ516619A (en) |
PL (1) | PL353741A1 (en) |
TR (1) | TR200200112T2 (en) |
WO (1) | WO2001005398A1 (en) |
ZA (1) | ZA200200464B (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001261471A1 (en) * | 2000-05-12 | 2001-11-26 | Smithkline Beecham Corporation | Phosphate transport inhibitors |
GB2378179A (en) * | 2001-08-03 | 2003-02-05 | Pantherix Ltd | Aromatic sulfonamides and their use in treating bacterial diseases |
AUPR738301A0 (en) * | 2001-08-30 | 2001-09-20 | Starpharma Limited | Chemotherapeutic agents |
US7119120B2 (en) * | 2001-12-26 | 2006-10-10 | Genzyme Corporation | Phosphate transport inhibitors |
AU2005299771A1 (en) | 2004-10-21 | 2006-05-04 | High Point Pharmaceuticals, Llc | Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use |
TW200637539A (en) * | 2005-01-20 | 2006-11-01 | Shionogi & Co | CTGF inhibitors |
JP2011523655A (en) * | 2008-06-03 | 2011-08-18 | フレセニウス メディカル ケア ドイッチュランド ゲーエムベーハー | Pharmaceutical composition comprising a gamma secretase modulator |
WO2018129556A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
CA2748607A1 (en) | 2008-12-31 | 2010-07-08 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
US8664425B2 (en) * | 2010-02-02 | 2014-03-04 | Honeywell International Inc. | Bluegreen fluorescent compounds |
JP5823514B2 (en) | 2010-07-07 | 2015-11-25 | アーデリクス,インコーポレーテッド | Compounds and methods for inhibiting phosphate transport |
WO2012006473A1 (en) | 2010-07-07 | 2012-01-12 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
EP2590510B1 (en) * | 2010-07-07 | 2016-09-28 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
EP2590965B1 (en) * | 2010-07-07 | 2016-04-20 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
US9382239B2 (en) | 2011-11-17 | 2016-07-05 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-terminal kinase (JNK) |
AU2013304812B2 (en) | 2012-08-21 | 2016-06-09 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
US10376481B2 (en) | 2012-08-21 | 2019-08-13 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
CN103183623A (en) * | 2013-03-12 | 2013-07-03 | 中国医学科学院医药生物技术研究所 | A group of benzene sulfonamido benzamide derivatives, and preparation and application thereof |
PT2983667T (en) | 2013-04-12 | 2019-07-11 | Ardelyx Inc | Nhe3-binding compounds and methods for inhibiting phosphate transport |
CN105395532B (en) * | 2015-11-25 | 2017-11-14 | 中国医学科学院医药生物技术研究所 | Application of the 2 benzene sulfonamido benzamide compounds in liver injury protection and liver fibrosis preventing and treating |
EP3508475A4 (en) * | 2016-08-30 | 2020-04-15 | Nippon Soda Co., Ltd. | Sulfonylamino benzamide compound and pest control agent |
US11242337B2 (en) | 2017-01-09 | 2022-02-08 | Ardelyx, Inc. | Compounds useful for treating gastrointestinal tract disorders |
BR112019013963A2 (en) | 2017-01-09 | 2020-04-28 | Ardelyx Inc | nhe-mediated antiport inhibitors |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL86462A (en) * | 1987-05-29 | 1992-12-01 | Fujisawa Pharmaceutical Co | Alkanesulfonanilide derivatives, processes for preparation thereof and pharmaceutical compositions comprising the same |
US5210079A (en) * | 1988-01-07 | 1993-05-11 | E. I. Du Pont De Nemours And Company | Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists |
-
2000
- 2000-07-18 AR ARP000103686A patent/AR030911A1/en not_active Application Discontinuation
- 2000-07-18 CO CO00053928A patent/CO5190714A1/en not_active Application Discontinuation
- 2000-07-19 AU AU63543/00A patent/AU6354300A/en not_active Abandoned
- 2000-07-19 WO PCT/US2000/019616 patent/WO2001005398A1/en active IP Right Grant
- 2000-07-19 TR TR2002/00112T patent/TR200200112T2/en unknown
- 2000-07-19 PL PL00353741A patent/PL353741A1/en not_active Application Discontinuation
- 2000-07-19 BR BR0012568-7A patent/BR0012568A/en not_active Application Discontinuation
- 2000-07-19 JP JP2001510455A patent/JP2003504403A/en not_active Withdrawn
- 2000-07-19 HU HU0202938A patent/HUP0202938A3/en unknown
- 2000-07-19 MX MXPA02000753A patent/MXPA02000753A/en unknown
- 2000-07-19 CN CN00810644A patent/CN1361687A/en active Pending
- 2000-07-19 IL IL14769700A patent/IL147697A0/en unknown
- 2000-07-19 CA CA002379657A patent/CA2379657A1/en not_active Abandoned
- 2000-07-19 EP EP00950437A patent/EP1202729A1/en not_active Withdrawn
- 2000-07-19 CZ CZ2002204A patent/CZ2002204A3/en unknown
- 2000-07-19 KR KR1020027000801A patent/KR20020015382A/en not_active Application Discontinuation
- 2000-07-19 NZ NZ516619A patent/NZ516619A/en unknown
-
2002
- 2002-01-18 ZA ZA200200464A patent/ZA200200464B/en unknown
- 2002-01-18 NO NO20020278A patent/NO20020278L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO20020278D0 (en) | 2002-01-18 |
NO20020278L (en) | 2002-01-18 |
TR200200112T2 (en) | 2002-05-21 |
NZ516619A (en) | 2004-02-27 |
ZA200200464B (en) | 2003-04-30 |
MXPA02000753A (en) | 2002-07-22 |
EP1202729A1 (en) | 2002-05-08 |
CZ2002204A3 (en) | 2002-11-13 |
CN1361687A (en) | 2002-07-31 |
CO5190714A1 (en) | 2002-08-29 |
AU6354300A (en) | 2001-02-05 |
BR0012568A (en) | 2002-04-30 |
JP2003504403A (en) | 2003-02-04 |
HUP0202938A3 (en) | 2006-07-28 |
HUP0202938A2 (en) | 2003-01-28 |
KR20020015382A (en) | 2002-02-27 |
CA2379657A1 (en) | 2001-01-25 |
PL353741A1 (en) | 2003-12-01 |
WO2001005398A1 (en) | 2001-01-25 |
IL147697A0 (en) | 2002-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR030911A1 (en) | USE OF N-ARIL-2-SULFONAMIDOBENZAMIDS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CHRONIC RENAL FAILURE AND PHARMACEUTICAL COMPOSITIONS | |
IL104311A (en) | Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same | |
EP1259487B8 (en) | 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors | |
FI102535B1 (en) | Process for the preparation of pharmaceutically useful 1,3,5-trisubstituted pyrazole derivatives | |
AR015769A1 (en) | PIRIDINE IMIDAZO DERIVATIVES THAT INHIBIT THE GASTRIC ACID SECRETION, PROCEDURE FOR THE PREPARATION OF SUCH DERIVATIVES, PHARMACEUTICAL COMPOSITION, USE OF SUCH DERIVATIVES FOR THE PREPARATION OF MEDICINES, AND INTERMEDIARY COMPOUNDS. | |
AR011134A1 (en) | DERIVATIVES OF IMIDAZO PIRIDINA SUBSTITUTED FOR THE INHIBITION OF THE GASTRIC ACID SECRETION; A SALT OF THE SAME, PROCEDURE FOR ITS PREPARATION, PHARMACEUTICAL FORMULATION THAT CONTAINS THEM AND THE USE OF SUCH COMPOUND FOR THE MANUFACTURE OF A MEDICINAL PRODUCT | |
BR9910915A (en) | Compound, processes for preparing a compound and for producing an antibacterial effect on a warm-blooded animal, use of a compound, and pharmaceutical composition | |
WO2003031442A1 (en) | Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof | |
MA24349A1 (en) | PROCESS FOR THE PREPARATION OF NEW INDOLE DERIVATIVES AND FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
KR930006024A (en) | Imidazo indolizine derivatives and preparation method thereof | |
CN103664734A (en) | Heterocyclic hydroxamic acid compound as well as pharmaceutical composition and application thereof | |
FR2804958B1 (en) | XANTHINE DERIVATIVES, PREPARATION METHOD AND INTERMEDIATES THEREOF, THEIR APPLICATION AS MEDICAMENT AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | |
KR880007081A (en) | Pharmaceutical preparations | |
CA2140781A1 (en) | Pharmocologically active .alpha.-¬tertiary-aminomethyl|- benzenemethanol derivatives | |
ECSP034533A (en) | SUBSTITUTE DERIVATIVES 5-AMINO-1 PENTENO-3-OL | |
NO20000654D0 (en) | 1,3-dioxolo / 4,5-H // 2,3 / benzodiazepine derivatives as AMPA / KAINAT receptor inhibitors | |
AR010644A1 (en) | COMPOUND 2-IMIDAZOLINYLAMINOBENZOTIAZOLE, PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND AND USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT | |
ATE306483T1 (en) | ALKOXY-SUBSTITUTED BENZIMIDAZOLE COMPOUNDS, DRUGS CONTAINING THEM AND THEIR USE | |
ATE372328T1 (en) | ANGIOGENESIS-INHIBITING 5-SUBSTITUTED-1,2,4-THIADIAZOLYL DERIVATIVES | |
IL83216A (en) | 1((5-(10->9)abeo-6-methylergolin-8beta-yl)methyl)-imidazolidine-(and hexahydropyrimidine)-2,4-dione derivatives,their preparation and pharmaceutical compositions containing them | |
ATE307131T1 (en) | PHENANTHROLINE-7-ONE DERIVATIVES AND THEIR THERAPEUTIC USE | |
ATE154603T1 (en) | HETEROCYCLIC ACIDS | |
ES8304996A1 (en) | Cephalosporins, process for their preparation and pharmaceutical compositions containing them. | |
DE59304138D1 (en) | NEW TRICYCLIC THIAZOLO AND THIAZINO DERIVATIVES AND ANITVIRAL DRUGS CONTAINING THEM | |
ES8305369A1 (en) | Cephalosporins, process for their preparation and pharmaceutical compositions containing them. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |